$34MSeries A, 12 November 2026
Orakl Oncology will use its Series A to expand oncology datasets, research staff, laboratory data generation, and cancer indications.
- Amount
- $34M
- Stage
- Series A
- Announced
- 12 November 2026
- Leads
- Norrsken VC, Singular
- Other investors
- InfraVia, Serena, Patient Autonome Fund managed by Bpifrance, teampact.ventures, Plug and Play, Verve Ventures, Speedinvest, HCVC, Thomas Wolf, Stan Polu
- Use of funds
- Expanding its dataset and Paris AI research, fivefold lab data, US and UK deployment teams, and therapeutic discovery.
- Total raised
- $50M to date
- Checked
- Amount and date matched across 2 press sources
- Sources
- Exclusive: Orakl Oncology raises $34m to test cancer drugs on ‘virtual patients’ sifted.eu
Orakl Oncology Raises $34M to Predict Cancer Clinical Trial Outcomes with 90% Accuracy hitconsultant.net